When inflation rises, investors often focus on obvious impacts like higher consumer prices or interest rates. However, a more profound transformation occurs beneath the market's surface—one that fundamentally reshapes how companies are valued. Understanding this mechanism gives investors crucial insight into why certain stocks plummet while others remain resilient during inflationary periods. The market's recent behavior tells a compelling story. A...
$ACADIA Pharmaceuticals (ACAD.US)$ Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med Acadia Pharmaceuticals (NASDAQ: ACAD) announced the publication of clinical data from the open-label DAFFODIL™ study in the journal Med, evaluating DAYBUE® (trofinetide) in Rett syndrome patients. The Phase 2/3 study focused on children aged 2-4 years (n=15) and demonstrated safety profiles consistent with previou...
$ACADIA Pharmaceuticals (ACAD.US)$Acadia Pharmaceuticals Announces DAYBUE Study Results In Med Journal; Open-Label DAFFODIL Study Shows Comparable Safety For Rett Syndrome in 2-4 Age Group; Results Support FDA Approval for Ages 2+ Benzinga· 5 mins ago Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the journal Medpublished results from the open-label study, DAFFODIL, evaluating the safety, tolerability and exploratory efficacy of DAYBUE (trofinetide) in girls ages two to fou...
$ACADIA Pharmaceuticals (ACAD.US)$ Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome 6 minutes ago, 6:00 AM PST Via BusinessWire ACAD Share -- Filing marks company's first Marketing Authorization Application in Europe Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tr...
$ACADIA Pharmaceuticals (ACAD.US)$Reuters· 1 min ago ACADIA Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
$ACADIA Pharmaceuticals (ACAD.US)$ Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711 Acadia Pharmaceuticals (NASDAQ: ACAD) has secured an exclusive worldwide license agreement with Saniona for SAN711, a first-in-class GABAA-α3 positive allosteric modulator. The company plans to develop SAN711 for essential tremor treatment, with Phase 2 studies expected to begin in 2026. Under the agreement, Saniona will receive a $28 million upfront payment plus potential ...
$ACADIA Pharmaceuticals (ACAD.US)$Reuters· 1 min ago ACADIA Pharmaceuticals Inc - Saniona to Receive $28 Million Upfront Plus up to $582 Million in Milestones with exclusive licensing agreement with Saniona for San711
$ACADIA Pharmaceuticals (ACAD.US)$Reuters· just ACADIA Pharmaceuticals Enters Into an Agreement to Sell Its Rare Pediatric Disease Priority Review Voucher for $150 Million
Report
No comment yet
Sign in to post a comment
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
ACADIA Pharmaceuticals Stock Discussion
The market's recent behavior tells a compelling story. A...
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
Acadia Pharmaceuticals (NASDAQ: ACAD) announced the publication of clinical data from the open-label DAFFODIL™ study in the journal Med, evaluating DAYBUE® (trofinetide) in Rett syndrome patients. The Phase 2/3 study focused on children aged 2-4 years (n=15) and demonstrated safety profiles consistent with previou...
Benzinga· 5 mins ago
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the journal Medpublished results from the open-label study, DAFFODIL, evaluating the safety, tolerability and exploratory efficacy of DAYBUE (trofinetide) in girls ages two to fou...
Can Acadia's Rett Syndrome Treatment Change Patient Lives? New Clinical Data Reveals Key Insights
Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome
6 minutes ago, 6:00 AM PST
Via BusinessWire
ACAD
Share
-- Filing marks company's first Marketing Authorization Application in Europe
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tr...
ACADIA Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
$Infobird Software (IFBD.US)$ Completed $40M acquisition. China stock. Low float. 0 shares LTB✅
$Ocean Power Technologies (OPTT.US)$ Form 4 insider buying. 0 shares LTB✅
$T Stamp (IDAI.US)$ Ran today. Up after hours. Possible catalyst. Low float. 0 shares LTB✅
$Syra Health (SYRA.US)$ Recent Form 4s multiple insider loading. Low fl...
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
Acadia Pharmaceuticals (NASDAQ: ACAD) has secured an exclusive worldwide license agreement with Saniona for SAN711, a first-in-class GABAA-α3 positive allosteric modulator.
The company plans to develop SAN711 for essential tremor treatment, with Phase 2 studies expected to begin in 2026. Under the agreement, Saniona will receive a $28 million upfront payment plus potential ...
ACADIA Pharmaceuticals Inc - Saniona to Receive $28 Million Upfront Plus up to $582 Million in Milestones with exclusive licensing agreement with Saniona for San711
ACADIA Pharmaceuticals Enters Into an Agreement to Sell Its Rare Pediatric Disease Priority Review Voucher for $150 Million
No comment yet